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The combination of cisplatin and capecitabine was evaluated in patients with recurrent or unresectable squamous cell carcinoma of
the head and neck (HNSCC), and outcome parameters were correlated with the expression of thymidine phosphorylase (TP),
thymidilate syntetase (TS), vascular endothelial growth factor receptor (VEGFR) 1–3, and microvessel density (MVD). Patients with
recurrent or unresectable HNSCC were eligible if they had received prior neoadjuvant chemotherapy, concurrent chemo-
radiotherapy, or no prior systemic therapy. Patients received cisplatin (75mgm
 2 day 1), and capecitabine (2000mgm
 2 day 1–14)
every 3 weeks. A total of 41 patients received 194 cycles. In all, 16 complete responses (39%) and 12 partial responses (29%) were
documented, for an overall response rate of 68% (95% CI, 53–80%). Grade 3–4 uncomplicated neutropenia was documented in
five subjects. Asthenia, anorexia, hand–foot syndrome, and constipation were the most frequent nonhaematologic events. Median
progression-free and overall survival were 6.4 and 12.6 months. Cytoplasmic TP expression was more prevalent in patients with a
laryngeal location vs other, and in patients with a recurrence vs primary disease. Microvessel density count was higher in patients with
recurrent vs primary disease. The combination of cisplatin and capecitabine is effective in recurrent or unresectable HNSCC, and
shows a manageable toxicity.
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Head and neck squamous cell carcinoma (HNSCC) accounts for
most malignancies that arise in the head and neck region (Liggett
and Forastiere, 1995). Two-thirds of the patients present with
advanced locoregional disease, and despite combined modality
approaches with chemotherapy and radiotherapy or surgery,
locoregional and distant failure occurs in up to 60 and 25% of
the patients, respectively, and the 3-year survival rate remains
below 30% (Dimery and Hong, 1993; Jacobs, 1994). The
combination of cisplatin and infusional 5-fluorouracil (5FU) is a
widely accepted schedule in the locally advanced or recurrent
disease setting, with response rates of 60–80 and 30–40%,
respectively; in the latter setting, median overall survival is 6
months (Campbell et al, 1987; Forastiere et al, 1992; Jacobs et al,
1992; Clavel et al, 1994).
Capecitabine (Xelodat) is an oral fluoropyrimidine prodrug
that is efficiently absorbed in the gastrointestinal tract and then
transformed by a sequence of reactions to 50-deoxy-5-fluorocyti-
dine (50DFCR), deoxyfluridine (50DFUR), and finally to 5-
fluorouracil (5FU) by thymidine phosphorylase (TP). Thymidine
phosphorylase is preferentially expressed in malignant cells and is
responsible for the higher intratumoral vs systemic 5FU concen-
trations found after capecitabine administration (Kono et al, 1983;
Takebayashi et al, 1996). Capecitabine results in tissue to plasma
5FU concentration ratios higher than intravenous 5FU (Ishikawa
et al, 1998a,b). The synergistic activity found between cisplatin
and 5FU prompted the evaluation of the combination of both
agents in a phase I, disease-directed study in 21 patients with
recurrent HNSCC; the recommended doses were cisplatin
100mgm
 2 on day one of a 21-day cycle, and capecitabine
1000mgm
 2 bid days 1–14 (Pivot et al, 2003).
Thymidine phosphorylase is a relevant target by being both an
angiogenesis-promoting factor, and the intracellular activator of
5FU prodrugs. This enzyme is widely expressed in humans cancers
(Zimmerman and Seidenberg, 1964), and higher levels of TP
expression are associated with increased intratumoral microvessel
density (MVD) and an unfavourable prognosis (Okamoto et al,
2001). Nuclear TP (TP-nuc) correlated with MVD, and was
inversely related with response and outcome in HNSCC patients
treated with 5FU, cisplatin and radiotherapy (Koukourakis et al,
2000). However, the relationship between these and other
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langiogenic-related factors, such as the expression of the vascular
endothelial growth factor receptors (VEGFR) 1–3, and outcome
parameters of HNSCC patients treated with cisplatin and
capecitabine, has not been explored. The present study addresses
these issues, while evaluating the feasibility and clinical activity of
the combination of cisplatin and capecitabine in recurrent or
unresectable HNSCC.
PATIENTS AND METHODS
Patient eligibility
Patients were required to have 18 years of age or older with
histologically documented HNSCC that was recurrent or unresect-
able, measurable disease, Karnofsky performance status (KPS)
X70, life expectancy of 12 weeks or longer, and adequate bone
marrow, hepatic and renal function (absolute neutrophil count
(ANC) X2.0 10
9l
 1, platelet count X100 10
9l
 1, haemoglobin
level X10.0gdl
 1, AST or ALT levels of o1.5 the upper limit of
normal, alkaline phosphatase level o5 the upper limit of
normal, normal bilirubin level, and a creatinine clearance
X50mlmin
 1). Patients could have received one prior regimen
of chemotherapy as neoadjuvant, adjuvant or concurrent therapy
with radiation, as long as it was terminated more than 6 months
before disease recurrence. Patients with grade 2 or higher
peripheral neuropathy or other serious medical or psychiatric
condition were excluded. The scientific review board of our
institution granted protocol approval. Patients were required to
provide written informed consent prior to enrolment into the
study. Within 3 weeks before study entry, a computed tomography
(CT) scan of the head and neck was performed. Within 1 week of
study entry, all patients had a complete clinical history and
physical examination, complete blood counts, serum biochemistry
tests (liver and renal function tests, and electrolytes), urinalysis,
and electrocardiogram.
Treatment plan
Treatment consisted of cisplatin (75mgm
 2 as a 30-min i.v.
infusion on day 1), followed by capecitabine (1000mgm
 2 orally
twice daily, on days 1–14), every 21 days. Standard mannitol and
i.v. hydration accompanied cisplatin administration. Prophylactic
antiemetics included i.v. ondansetron (8mg) prior to chemother-
apy, and oral ondansetron 4mg three times daily for 2 days.
Treatment was administered on an outpatient basis for a
maximum of six cycles. Re-treatment on day 22 required an
ANC count X1.5 10
9l
 1, a platelet count X100 10
9l
 1,a
creatinine clearance rate 450mlmin
 1, and resolution of all
nonhaematological toxicities (except alopecia and fatigue) to
baseline or less than grade 1. In case of a delay longer than 14
days, the patient was removed from the study. The doses of
cisplatin and capecitabine were reduced following specific guide-
lines. Toxic events were recorded on a continuous basis, and
followed until they were resolved to baseline or less than grade 1.
Treatment compliance was evaluated using patient diaries and
accounting unused drug. History and physical examination,
complete blood cell counts, and serum biochemistry tests were
performed at weekly intervals during treatment. Re-staging CT
scans, chest radiographs, and upper respiratory tract examinations
were performed every 3 cycles (9 weeks), or when clinically
indicated.
Study end points
The primary end point of the study was tumour response. The
criteria used to define response were standard RECIST criteria
(Therasse et al, 2000). Secondary efficacy parameters were
progression-free survival (PFS) and overall survival (OS). Progres-
sion-free survival and OS were defined as the time from diagnosis
of recurrent or advanced disease to the last contact, or progression
or death, respectively. Adverse events were classified and graded
according to the National Cancer Institute Common Toxicity
Criteria version 3.0. Patients were considered evaluable for
response and toxicity once therapy was initiated.
Tissue microarray (TMA) design
A tissue arrayer device (Beecher Instrument, Silver Spring, MD,
USA) was used to construct the TMAs. All slides were reviewed by
expert pathologists (MRP and JLRP) to select areas containing
tumour cells and to exclude those areas showing necrosis,
inflammation, and queratinisation. To assess reproducibility,
cylinders of 0.6mm in diameter from two different areas were
taken in each case. Tissue microarray blocks were constructed with
the duplicated test sample and 12 controls. The latter specimens
were used to ensure the quality, reproducibility, and homogenous
staining of the slides, and consisted on archival reactive tonsil
tissue. The samples were blindly scored, and when discordances
between the duplicated specimens occurred an additional area was
considered.
Immunohistochemistry
Sections (3-mm thick) were cut from the TMA and transferred to
silanised glass slides. The sections were dried for 16h at 561C
before being de-waxed in xylene and re-hydrated through a graded
ethanol series and washed with phosphate-buffered saline. For
antigen retrieval a treatment in a pressure cooker for 15min in
citrate buffer at 951C was performed. Immunohistochemical
staining was performed in an automated immunostainer, using
the biotin–streptavidin-peroxidase procedure with diaminobenzi-
dine as the chromogen. Haematoxilin was used for counter-
staining. The following antigens were stained: TS (TS 106,
Neomarkers, MS-471, 1:10 LSAB), thymidine phosphorylase
(PD-ECGF Ab-1, Neomarkers, PGF.44C, prediluted during
30min), VEGF-R1/ Flt-1 (h-225) (Polyclonal rabbit, Santa Cruz,
1/800), VEGFR2/FLK-1 (Monoclonal A-3, Santa Cruz Biotechnol-
ogy, Inc., 1/50), VEGF-R1/FLT-1 (C-17) (Policlonal rabbit, Santa
Cruz, 1/150). Reactivity for all antibodies was quantified by use of
a visual grading system based on the intensity of cytoplasm
staining (0–2) as follows: grade 0: no immunoreactivity, grade 1: if
any specific staining, slightly stronger than background staining
was detected, and grade 2: if clear immunoreactivity in more than
half of the cancer cells were detected. The association of histologic
factors with site of disease, type of disease, stage, and response to
treatment was analysed; the impact of these factors on progres-
sion-free and overall survival was evaluated. Assessment included
both no vs any expression, as well as no plus low vs high
expression.
Microvessel counting
Blood vessels were visualised by staining endothelial cells for CD31
(Mouse monoclonal antibody JC70, Dako, Prosan, Belgium). One
section per tumour was analysed. The entire section was analysed
at  20–40 magnification to identify the areas of most intense
neovascularisation, that were identified as having the highest
density of brown staining. Vascular hotspots were suitable for
analysis provided they were adjacent to tumour cells. Whenever
such a highly vascularised area was encountered at  20–40
magnification, individual microvessels were counted and ex-
pressed as microvessels per field (MPF) at  200 magnification.
Neither vessel lumens nor the presence of red blood cells was used
to define a microvessel, and no exclusion criteria based on size
were used. The mean of the five highest counts per tumour was
taken for further analyses. The predefined cutoff value for
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lcategorical evaluation of MVD was the median of the MVD of the
population studied.
Statistical analysis
The trial followed a two-stage Simon Minimax design (Thall et al,
1989), allowing early closure in case of treatment failure. The null
hypothesis of a true response rate of 50% or lower was evaluated
against the alternative hypothesis of a true response rate of 70% or
higher (alpha error 0.05, beta error 0.20). In all, 13 responses were
required in the first 23 patients to continue accrual, and 24
responses out of 37 patients were required to consider the regimen
promising. Confidence intervals (CIs; 95%) were calculated with
the exact method. Survival was estimated by the Kaplan–Meier
product limit method (Kaplan and Meier, 1958). A Cox propor-
tional hazards model was created to assess prognostic or predictive
factors in a multivariate fashion. All tests were two-sided at the
0.05 level of significance. The SPSS (version 10.0, Chicago, USA)
package was used for statistical analyses.
RESULTS
Patients
Between November 2001 and November 2002, 41 patients with
locally advanced HNSCC were accrued into the study. All patients
were assessable for toxicity and survival, and response could be
evaluated in 40 patients. Demographic and clinical characteristics
of the subjects are summarised in Table 1. A total of 18 patients
presented a relapse from a previously diagnosed and treated
HNSCC, that was locoregional in 14 cases, and both locoregional
and distant in four patients (three lung, one skin). Four patients
presented a second primary HNSCC, and 19 patients presented
with unresectable disease at diagnosis; for the latter two groups,
treatment was delivered as induction therapy. Nine patients had
received prior chemotherapy; five (56%) had been treated with a
combination of cisplatin, 5-FU and paclitaxel as neoadjuvant
chemotherapy, and four (44%) had received cisplatin alone as
concurrent chemoradiotherapy. In all, 15 patients had received
radiotherapy. The median interval between initial diagnosis and
relapse or second primary occurrence was 14 months (range 6–53
months).
Treatment administered
A total of 195 cycles of the study regimen were delivered (median
five cycles; range 2–6 per patient): 20 patients (49%) received the
six planned cycles, seven (17%) received five cycles, three (7%)
received four cycles, six (15%) received three cycles, and five
(12%) received two cycles. Most chemotherapy cycles were
delivered at the planned doses (94%), and schedules (88%). Doses
were reduced in 10 patients (due to seven, one and one episodes of
haematologic toxicity, diarrhoea, and hand–foot syndrome (HFS),
respectively). Treatment was delayed for a week in 15 patients (due
to 13, 1, and 1 episodes of haematologic toxicity, mucositis, and
HFS, respectively). Median treatment duration was 16 weeks
(range 6–20). Median dose intensities were 25mgm
 2 per week of
cisplatin (range 15.5–25), and 8.8gm
 2 per week of capecitabine
(range 5.8–9.3). Median dose intensities achieved for cisplatin and
capecitabine were 100 and 95% of the planned doses, respectively.
Response
In total, 15 responses were documented in the first stage (23
patients), and thus accrual continued. The overall response rate
was 68% (28 out of 41 patients; 95% CI, 53–80%) (Table 2). There
were 16 complete responses (39%), 12 partial responses (29%), five
disease stabilisations (12%), and seven patients (17%) presented
progressive disease as the best response to therapy. One patient
(3%) was removed from the study due to cardiac toxicity before
response assessment. Median time to response was 9 weeks (range,
8–10 weeks). Median duration of response was 5.6 months (range,
2.4–21 months; 95% CI, 4.2–6.9 months). All patients who
ultimately achieved a clinical response were responding by cycle 3,
but only 11 out of the 16 complete responses were achieved after
three cycles of therapy. No differences were noted comparing
response in untreated vs previously treated with cisplatin and/or
Table 1 Patient characteristics
Patients (n¼41)
Characteristic No. %
Sex
Male 39 95
Female 2 5
Age (years)
Median 54
Range 33–73
Karnofsky performance status
90 11 27
80 24 58
70 6 15
Initial staging at diagnosis
II 4 10
III 5 12
IV 32 78
Primary tumour site
Oral cavity 13 32
Oropharynx 12 29
Hypopharinx 5 12
Larynx 11 27
Extent of disease
Recurrent disease
Locoregional recurrence 14 34
Locoregional and distant recurrence 4 10
Primary disease
First primary 19 46
Second primary 4 10
Prior therapy
Surgery alone 7 17
Surgery+radiotherapy 6 15
Surgery+radiotherapy+chemotherapy 5 12
Chemotherapy+radiotherapy 4 10
None 19 46
Table 2 Response to treatment
Patients (n¼41)
No. %
Overall response 28 68
95% CI 53–80
Complete response 16 39
Partial response 12 29
Stable disease 5 12
Progressive disease 7 17
Nonassessable 1 3
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the response rate in relapsed subjects according to prior target
irradiation, a trend towards a better clinical response rate was
documented in nonradiated vs radiated targets (85 vs 45%;
P¼0.09).
Toxicity
Haematologic and nonhaematologic toxicities are shown in Table 3.
Grade 3–4 neutropenia was documented in five subjects, but no
febrile neutropenic episodes were recorded. Median nadir ANC
count was 2.2 10
9l
 1 (range, 0.34–11.2 10
9l
 1). Thrombocy-
topenia was observed in six patients (15%), that was grade 3 in one
subject (2%). Anaemia was documented in 29 patients (71%), and
was grade 3 in three subjects (7%). Asthenia, anorexia, HFS, and
constipation were the most frequent nonhaematologic events. Nine
out of 41 patients (22%) suffered from grade 3 or 4 nonhaema-
tologic adverse events, being the most frequent asthenia and
anorexia (three grade 3 episodes each), and mucositis (two grade 3
events); the latter was unrelated to prior radiotherapy. Only one
patient suffered from grade 3 HFS. One 47-year-old woman with a
past history of smoking presented an episode of exercise-related
angor pectoris on day 12 of the second cycle of therapy that
responded to calcium-channel blockers, and was thought related to
capecitabine administration; subsequently, she was removed from
the study. Table 4 shows toxicity by treatment cycle.
Subsequent therapy and outcome
After completion of the study treatment, patients with disease
control or unassessable were treated with radiotherapy (12),
surgery plus radiotherapy (five), surgery (four), and 13 received no
further therapy. Patients with progressive disease as the best
response were treated with chemotherapy (four), chemotherapy
and radiotherapy (two), and best supportive care (one).
In all, 33 patients have progressed; 27 patients recurred
locoregionally, two patients presented distant metastases, and
four patients presented both locoregional and distant disease.
Median PFS was 6.4 months (95% CI, 5.7–7.3 months), and
median survival after disease progression was 3 months (95% CI,
0.7–5.3 months). A total of 23 deaths have occurred, all of them
related to tumour progression. Median overall survival was 12.6
months (95% CI, 10.0–15.2 months) (Figure 1). The multivariate
model showed that achieving a complete response marginally
predicted a better OS (P¼0.041).
Comparison of patients with recurrent and primary
unresectable disease
Results are summarised in Table 5. Response rates were similar
between patients with recurrent disease and those with primary
unresectable disease (61 vs 74%, respectively; P¼0.50), although
there was a trend towards a higher incidence of progressive disease
in the recurrent group (9 vs 28%, P¼0.10). Toxicity was equivalent
between groups. PFS (6.5 vs 5.9 months, P¼0.40) and OS (12.7 vs
12.9 months, P¼0.73) showed no differences when comparing
patients with recurrent and primary unresectable disease, respec-
tively (Figure 2). However, the proportion of patients free of
relapse at the moment of this analysis was marginally higher in
patients with primary tumours (6 vs 30%, P¼0.046).
Immunohistochemical evaluation
Tumour tissue from 31 patients was assessed. The levels of
expression of TS, TP-cyt, TP-nuc, and VEGFR1 to 3 are shown in
Table 6. The only factor that showed a significant association with
any clinical or outcome parameters was TP-cyt (Table 7). High TP-
cyt expression was more prevalent in patients with a laryngeal
location than in those with neoplasms arising from other locations
(83 vs 24%; P¼0.009). In addition, a higher percentage of patients
with a recurrence expressed high levels of TP-cyt when compared
with those with primary disease (64 vs 12%; P¼0.007). No
Table 3 Summary of haematologic and nonhaematologic toxicity
All grades Grade 3–4
No. of patients % No. of patients %
Haematologic
Anaemia 29 71 3 7
Neutropenia 17 42 5 12
Thrombocytopenia 6 15 1 2
Nonhaematologic
Asthenia 36 88 3 7
Anorexia 34 83 3 7
Hand–foot syndrome 27 66 1 2
Constipation 26 63 0 0
Nausea/vomiting 16 39 0 0
Alopecia 12 29 — —
Mucositis 11 27 2 5
Neuropathy 4 10 0 0
Diarrhoea 3 7 1 2
Cardiotoxicity 1 2 1 2
Table 4 Toxicity by treatment cycle
Cycle
1( n¼41) 2 (n¼40) 3 (n¼36) 4 (n¼30) 5 (n¼27) 6 (n¼20)
Grade 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Anaemia 6 1 0 0 11 1 1 0 7 2 1 0 12 3 0 0 7 6 1 0 9 2 1 0
Neutropenia 2 1 0 1 2 0 2 1 4 1 1 0 2 2 0 0 2 1 1 0 3 0 0 0
Thrombopenia 1 0 0 0 2 0 0 0 1 0 0 1 1 2 0 0 1 0 0 1 0 1 0 0
Asthenia 16 8 0 0 18 9 1 0 18 8 1 0 15 8 1 0 14 8 2 0 10 8 0 0
Anorexia 8 3 0 0 11 8 0 0 16 6 1 0 11 7 1 0 14 8 2 0 11 6 0 0
Hand–foot 0 0 0 0 0 1 0 0 8 2 0 0 16 3 1 0 8 10 1 0 6 11 0 0
Constipation 11 2 0 0 12 4 0 0 9 3 0 0 12 1 0 0 11 2 0 0 6 3 0 0
Nausea/vomiting 6 1 0 0 5 0 0 0 4 0 0 0 2 3 0 0 2 0 0 0 1 1 0 0
Alopecia 0 0 — — 2 0 — — 9 0 — — 8 0 — — 8 1 — — 7 0 — —
Mucositis 3 1 2 0 2 2 1 0 2 1 0 0 2 0 0 0 1 0 0 0 0 0 0 0
Neuropathy 0 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 1 0 0 2 1 0 0
Diarrhoea 0 0 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
Cardiotoxicity 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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lsignificant correlation was found between TP-cyt and TP-nuc
(Pearson, r¼0.23; P¼0.22). No other differences were found.
MVD count was higher in patients with a recurrence than in those
with primary disease (3177 vs 2376 MPF; P¼0.012). There were
no differences in MVD when stratifying patients according to
clinical characteristics, or the expression of other histologic
factors. No significant correlation was found between MVD and
TP-cyt (Pearson, r¼0.28; P¼0.15), or TP-nuc (Pearson,
r¼ 0.15; P¼0.47). Patients with an MVD above the median (23
MPF) showed a trend towards a longer OS compared to those with
an MVD below the median (12.9 vs 10.1 months; P¼0.074).
DISCUSSION
The combination of cisplatin and capecitabine at the doses
evaluated showed a significant level of activity, and a good
tolerability. The median number of cycles administered and the
dose intensity achieved highlight the feasibility of this regimen.
Although it was not the purpose of this trial, and with due caution
considering the limited sample size, it is not adventurous to affirm
that this regimen shows at least a similar level of activity as that of
cisplatin and infusional 5FU. The relative heterogeneity of this
cohort of patients permitted to establish a number of thought-
provoking comparisons. No difference in terms of efficacy was
observed between patients with a relapse and those with primary
disease, nor was any dissimilarity evidenced between cisplatin and/
or 5FU-treated and previously untreated subjects. Also, the
response rate according with prior target irradiation was
nonsignificantly higher in nonradiated patients. However, con-
sidering the low number of patients analysed, these observations
have to be interpreted with caution.
Interestingly, all patients who ultimately responded had
significant tumour shrinkage after three cycles, an observation
that emphasises the activity of the regimen; notwithstanding, five
out of 16 complete responders needed four or more cycles to
achieve a maximal effect. This observation may be relevant in
decision-making strategies, for it may indicate that only those
patients responding by cycle three will benefit from further
therapy.
PFS
Months
18 12 6 0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
Patients     41
Events       33    (80%) 
Censored      8    (20%) 
Median        6.5 (mos) 
OS
Months
18 12 6 0
Patients        41 
Events          23   (55%)
Censored     18   (44%)
Medianc       12.7 (mos) 
Figure 1 Progression-free survival and OS for the whole series of
patients.
Table 5 Comparison between patients with recurrent and primary
unresectable disease
Recurrent disease
(n¼18)
Primary disease
(n¼23)
No. % No. %
Response
Overall response 11 61 17 74
95% CI 38–80 53–87
Complete response 6 33 10 44
Partial response 5 28 7 30
Stable disease 1 6 4 17
Progressive disease 5 28 2 9
Nonassessable 1 6 0 0
Further therapy
Radiotherapy 2 11 10 44
Surgery 2 11 2 9
Surgery plus radiotherapy 1 6 4 17
Chemotherapy 4 22 0 0
Chemotherapy plus
radiotherapy
0029
None 9 50 5 22
Relapses
No relapse 1 6 7 30
Locoregional 12 67 15 65
Distant 1 6 1 4
Locoregional plus distant 4 22 0 0
OS PFS
Months
18 12 6 0
1.0
0.8
0.6
0.4
0.2
0.0
Months
18 12 6 0
1.0
0.8
0.6
0.4
0.2
0.0
Figure 2 Comparison of PFS and OS in recurrent (þ) vs primary
unresectable (r) patients.
Table 6 Level of expression of TS, TP-cyt, TP-nuc, and VEGFR 1–3
No expression (%) Low expression (%) High expression (%)
TS 7 (23) 14 (47) 9 (30)
TP-cyt 7 (23) 13 (42) 11 (35)
TP-nuc 13 (42) 13 (42) 5 (16)
VEGFR 1 18 (58) 13 (42) 0 (0)
VEGFR 2 1 (3) 4 (13) 26 (84)
VEGFR 3 1 (3) 27 (87) 3 (9)
TP-cyt: cytoplasmic thymidine phosphorylase; TP-nuc: nuclear thymidine phosphor-
ylase; TS: thymidine synthase; VEGFR: vascular endothelial growth factor receptor.
Table 7 Correlation of the levels of expression of cytoplasmic thymidine
phosphorylase (TP-cyt) with clinical features
TP-cyt
No or low
expression (%)
High expression
(%) P
Primary tumour site
Oral cavity 6 (55) 5 (45)
Oropharynx 9 (90) 1 (10) 0.009
Hypopharinx 4 (100) 0 (0)
Larynx 1 (17) 5 (83)
Type of disease
Recurrence 5 (36) 9 (64) 0.007
Primary 15 (88) 2 (12)
TP-cyt: cytoplasmic thymidine phosphorylase.
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lToxicity was moderate and manageable; anaemia was the main
haematologic toxicity and was predominantly grade 1. Neutrope-
nia was documented in five patients but none of them developed
related infectious complications. This profile of haematological
toxicity is lower than that consistently reported with cisplatin–
5FU (Forastiere et al, 2003). The most common nonhaematologic
toxicities were asthenia, anorexia, HFS, and constipation. Of note,
a patient developed angor pectoris while receiving capecitabine, an
event that highlights the pharmacologic similarities of this drug to
infusional 5FU. The toxicity profile appears to be milder to that
reported by Pivot et al (2003), even considering that the average
number of cycles per patient is higher in the current study (2.5 vs
4.8 cycles per patient (median not reported)). Also efficacy in the
present study was higher. Differences in patient population may
explain these findings; in fact, all patients enrolled in that phase I
study had been previously treated with chemotherapy, as opposed
to only 22% of patients in this study. However, the higher dose of
cisplatin used (17 out of 21 patients received 100mgm
 2) may be
partially responsible for the increased incidence of adverse events;
in view of the efficacy of the current schedule and the relative
equivalency of lower vs higher doses of cisplatin in advanced
HNSCC patients (Veronesi et al, 1985), 75mgm
 2 seems to be a
reasonable cisplatin dose to administer in combination with
capecitabine.
As long as it maintains equivalent efficacy, patients generally
prefer oral administration of chemotherapy to intravenous
infusions (Liu et al, 1997), but oral therapy may theoretically be
difficult in patients with HNSCC who frequently have swallowing
dysfunction related either to their tumour or its treatment.
However, this was not the case in the present report, a fact
underlined by the high compliance with oral chemotherapy
documented (98%).
Tumour angiogenesis manifested as increased MVD counts or
VEGF expression has been shown to adversely impact outcome
and treatment results in HNSCC patients in several series (O-
Charoenrat et al, 2001; Mineta et al, 2002). After analysing 94
patients with unresectable HNSC treated with chemoradiation,
Koukourakis et al (2000) concluded that TP-nuc expression was
associated with angiogenesis as assessed by MVD, with resistance
to radiotherapy and cytotoxic therapy, and with poorer survival in
squamous cell head and neck cancer. TP is a pertinent factor to be
assessed in this clinical context given its unique duality: it is both
the activator of one of the drugs administered (and thus with
potential predictive capability), and a potent proangiogenic factor.
Recently, Brown et al (2000) showed that TP induces oxidative
stress to cancer cells, and promotes secretion of angiogenic factors
such as VEGF. In the present report, TP-cyt expression was found
to be significantly more prevalent in patients with laryngeal cancer
compared with other locations, and in relapsed patients. The
significance of the former finding remains obscure, whereas the
latter observation may be related to the aggressiveness of the
disease. The second potential predictive factor of response
assessed was TS. A previous study shows that low intratumoral
expression of TS was a strong predictor of response to 5FU-based
therapy of disseminated colorectal cancers, and strongly correlated
with a longer survival (Leichman et al, 1997). However, no
relationship was found between TP (either nuclear or cytoplas-
matic) or TS and activity in the current series. The levels of the
VEGFR are correlated with a poorer grade of tumour differentia-
tion and prognosis in pancreatic cancer (Buchler et al, 2002). The
fact that in the current series the majority of patients expressed
high levels of VEGFR2 but none expressed high levels of VEGFR1,
together with the lack of correlation with MVD, suggests that the
sensitivity and/or specificity of the technique may not be optimal.
However, and this also applies to TP/TS expression, the
interpretation of these results is constrained by the relatively low
number of patients analysed.
MVD count was significantly higher in relapsed patients than in
those with primary disease, and it could be hypothesised that a
higher MVD in recurrences indicates a more aggressive behaviour,
but the present study is underpowered to address this issue. The
fact that both MVD and TP-nuc were concomitantly elevated in
relapsed patients may indirectly confirm the association between
these two factors in prior reports (Koukourakis et al, 2000). It is
also somehow paradoxical that patients with an MVD above the
median showed a trend towards a better outcome; however, the
multivariate analysis showed no relationship between MVD (either
as a continuous value of grouping according to the median) and
OS. It is increasingly evident that univariate results from studies
involving analysis of biologic factors have to be cautiously
interpreted, considering the numerous stratifications and compar-
isons performed.
In summary, this cisplatin–capecitabine schedule in recurrent
or unresectable HNSCC is feasible and effective in terms of tumour
response, and comparative, multicentre trials with cisplatin–5FU
seem warranted.
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